Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31338758 | 0.85 | CYP1A2 (0.31) | — | |
| SCHEMBL15241715 | 0.83 | RAPGEF4 (0.35) | — | |
| SCHEMBL24357673 | 0.80 | KDM1A (0.37) | TRPA1ALDH1A1TSHR | |
| SCHEMBL29738508 | 0.79 | KIF11 (0.33) | — | |
| SCHEMBL24852353 | 0.79 | KIF11 (0.33) | — | |
| SCHEMBL27161330 | 0.79 | HTR2A (0.38) | ALDH1A1TSHR | |
| SCHEMBL6167933 | 0.78 | MEP1B (0.46) | TRPA1ALDH1A1TSHR | |
| SCHEMBL25219828 | 0.78 | TRPA1 (0.32) | TRPA1ALDH1A1TSHR | |
| SCHEMBL4547659 | 0.78 | HDAC1 (0.35) | TRPA1ALDH1A1TSHR | |
| SCHEMBL7762516 | 0.78 | TDP1 (0.40) | CES2CES1MAOBRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119465288-A | Anion exchange membrane, preparation method and application thereof, and electrolysis device | 氢和元泰(常州)新材料科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-118063504-A | Fluoro phenyl phosphate compound, perovskite thin film, perovskite solar cell, preparation method, electric equipment and application | 天合光能股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-122055361-A | Fascin inhibitors | 北京双鹤润创科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260125365-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2026-05-07 | — | — | US | disclosed |
| EP-4720054-A1 | FASCIN INHIBITORS | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| US-12559474-B2 | Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-1568754-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION CONTAINING INDAN COMPOUND | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
| CN-1443164-A | Pyrrolidine derivatives as metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | CN | disclosed |
| CN-1391562-A | Quinazoline derivatives as medicaments | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | CN | disclosed |
| EP-1218354-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| CN-1073112-C | Optionally substituted 8-cyano-1-cyclopropyl-7- (2, 8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid and derivatives thereof | BAYER AG (DE) | 2001-10-17 | — | — | CN | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | CES2 4190/4885CES1 2645/4885TRPA1 4747/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CES2 2983/4885CES1 626/4885TRPA1 4406/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CES2 2350/4885CES1 522/4885TRPA1 3826/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | CES2 277/4885CES1 145/4885TRPA1 3385/4885 |
| US-12559474-B2 | Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | NSUN2, ZC3HAV1, IFNAR1 | CES2 522/4885CES1 455/4885TRPA1 4823/4885 |
| US-20260125365-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACE2, ACE, SARS1 | CES2 449/4885CES1 160/4885TRPA1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.